Navigation Links
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
Date:2/20/2008

post- operative inflammation and uveitis; ganciclovir, a topical antiviral for herpetic keratitis; cyclosporine, a topical immunomodulator for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist for geographic atrophy associated with dry AMD. In addition, Sirion has preclinical programs in back of the eye diseases and allergy. For more information, please visit http://www.siriontherapeutics.com .

About Bridge Pharma, Inc.

Bridge Pharma, Inc. is a privately held pharmaceutical research and development company located in Sarasota, FL. Bridge Pharma was founded in 1996 by Dr. Gunnar Aberg, currently CEO. In addition to the current license with Sirion Therapeutics, Bridge has out-licensed internally developed drugs for growth promotion, heaves in horses, obesity, pain, over-active bladder and urinary incontinence. Bridge is committed to the discovery, research and development of NCEs that provide therapeutic treatment for unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements and information about Sirion Therapeutics, Inc.'s and Bridge Pharma Inc.'s business and products. These forward-looking statements are only business forecasts. Actual results may differ from the results anticipated, expressed or implied by these forward-looking statements and are dependent upon, among other things, drug applications and regulatory authorizations.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
4. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
5. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
6. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
7. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
8. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
11. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... DIEGO, March 16 Prometheus Laboratories Inc., a specialty ... received New York State approval for PROMETHEUS(R) IBS Diagnostic, ... syndrome (IBS). This novel test incorporates 10 biomarkers, ... algorithm to help physicians diagnose patients with IBS."One out ...
... N.J., March 16 DOR BioPharma, Inc. (OTC Bulletin ... it has appointed Gregg Lapointe, CPA, MBA, to its ... Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company ... patients with rare diseases. Sigma-Tau is DOR,s North American ...
... experts will address the benefits of rigorous early phase ... American Society for Clinical Pharmacology and Therapeutics (ASCPT), to ... Harbor, Maryland from March 18 - 21, 2009. The ... be to help biopharmaceutical companies understand best practice approaches ...
Cached Biology Technology:Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 3DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 4PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4
(Date:9/17/2014)... Transmission of bacterial infections, including MRSA and MSSA ... microscopic bumps that mimic the scaly surface of ... open access journal Antimicrobial Resistance and Infection ... different materials prevented the spread of human disease ... named Sharklet, is an arrangement of ridges formulated ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... A new report demonstrates how a sensitive imaging ... bacteria in chronic infections. Listeria monocytogenes is ... illness and death. Listeria outbreaks recently claimed twenty ... most common cause of bacterial meningitis in newborns, and ...
... for simple taskswould have smiled at one of leptin,s mechanisms ... fat-derived hormone enlists the sympathetic nervous system to prevent bone-making ... discharge insulin. The study will appear online December 22, ... print issue of The Journal of Cell Biology ...
... the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News.,Please credit the ... the source for this information. ALL CONTENT ... is embargoed for 9 a. m., Eastern Time, ...
Cached Biology News:New research lights up chronic bacterial infection inside bone 2Leptin's long-distance call to the pancreas 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 3American Chemical Society's Weekly PressPac -- Dec. 17, 2008 4American Chemical Society's Weekly PressPac -- Dec. 17, 2008 5American Chemical Society's Weekly PressPac -- Dec. 17, 2008 6American Chemical Society's Weekly PressPac -- Dec. 17, 2008 7American Chemical Society's Weekly PressPac -- Dec. 17, 2008 8
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: